News

Epcoritamab plus lenalidomide reduced the risk of disease progression or death vs R-GemOx in relapsed/refractory DLBCL in the EPCORE DLBCL-4 trial.

The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

The European Union has approved trastuzumab deruxtecan for patients with previously treated, HER2-positive metastatic solid tumors.

A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.

SB27, a proposed pembrolizumab biosimilar, met primary end points in phase 1 pharmacokinetic and a phase 3 efficacy studies.

Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The enzalutamide bioequivalent received tentative FDA approval, pending patent expiry on branded Xtandi before final marketing authorization.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

Real-world treatment with pegylated interferon alfa-2a tolerable, and treatment-related AEs were manageable in patients with cutaneous T-cell lymphoma.

The FDA approved a prefilled pen for the administration of ropeginterferon alfa-2b-njft in adult patients with polycythemia vera.

Translational profiling tied CCR4 loss, IL enrichment, and BCL-2 upregulation to mogamulizumab resistance; venetoclax may be a combination partner.

In a phase 1 trial, duvelisib plus nivolumab produced a 26% overall response rate in relapsed/refractory cutaneous T-cell lymphoma but was limited by immune-mediated toxicities.

Real-world mogamulizumab reduced skin symptoms and improved health-related quality of life in patients with mycosis fungoides and Sézary syndrome.

CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.

CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.

Dibotatug was deemed tolerable and produced robust responses across subgroups of patients with relapsed/refractory cytotoxic T/NK cell lymphomas.

BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.

The final analysis of the Italian FIL-MOGA study showed an objective response lasting at least 4 months in 47% of patients and identified the measure as a surrogate for survival outcomes.

The CHMP has recommended datopotamab deruxtecan for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

Roswell Park Comprehensive Cancer Center announces the release of an operative surgical manual for surgeons performing bladder cancer surgeries.

The resubmission of the BLA for RP1 has been accepted for review by the FDA for its use in combination with nivolumab in advanced melanoma.

R. Lor Randall, MD, FACS, reviews a longitudinal study in osteosarcoma showing a strong correlation between ctDNA status and clinical outcomes such as EFS.